Artin Bioscience, founded with a mission to develop and provide innovative therapies for respiratory diseases, focuses on conditions such as COVID-19, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), and Pulmonary Arterial Hypertension (PAH). The company leverages novel mechanisms of action based on cell biology to address unmet medical needs in these areas, aiming to improve patient outcomes and quality of life.
Notable figures associated with Artin Bioscience include Dr. Norbert Voelkel, who is part of the team and advisory board. The company has made significant strides in the development of therapeutics for critical respiratory conditions, contributing to advancements in medical treatments for diseases with high morbidity and mortality rates. Through its dedicated research and innovative approach, Artin Bioscience is making a substantial impact on the field of respiratory medicine.
